⚄⤒ኚᛶ⑌ᝈ◊✲ᐊ⚄⤒ኚᛶ⑌ᝈ◊✲ᐊ
㸿㸬ㄽᩥ
ձཎⴭ
Ḣᩥㄽᩥ
A㸫ձ
1. Yoshiyama Y, Kojima A, Ishikawa C, Arai K. Anti-inflammatory action of Donepezil
ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mousemodel. J Alzheimer dis. 22: 295-306, 2010.
㹀㸬Ꮫ఍Ⓨ⾲ձᅜ㝿Ꮫ఍
B㸫ձ
1. Yoshiyama Y: High calorie diet enhanced, but voluntary exercise restored taupathology in a tauopathy model mouse. Alzheimer's association international
conference on Alzheimer's disease, 2010.7.11-15 Honolulu, Hawaii.ղᅜෆᏛ఍
B㸫ղ
1. ᪂஭බேࠊྜྷᒣᐜṇࠊఀ⸨႐⨾Ꮚࠊ᪩ᕝ┬ ẚ㍑ⓗⰋዲ࡞⤒㐣ࢆ࿊ࡍࡿ⑕౛࠿ࡽࡳࡓ CJDࢧ࣮࣋࢖ࣛࣥࢫࡢၥ㢟Ⅼ ➨ 51 ᅇ᪥ᮏ⚄⤒Ꮫ఍⥲఍, 2010.5.20-22 ᮾி2. ྜྷᒣᐜṇࠊ▼ᕝ༓ᜨᏊࠊ᪂஭බேࠊఀ⸨႐⨾Ꮚ ࣓ࢱ࣎ࣜࢵࢡࢩࣥࢻ࣮࣒ࣟ࡜⚄⤒ኚᛶ㸸ࢱ࢘࢜ࣃࢳ࣮ࣔࢹ࣐ࣝ࢘ࢫࢆ⏝࠸ࡓ᳨ウ ➨ 51 ᅇ᪥ᮏ⚄⤒Ꮫ఍⥲఍, 2010.5.20-22 ᮾி
3. ᯽ᡞᏕ୍ࠊྜྷᒣᐜṇ: ࢔ࣝࢶࣁ࢖࣐࣮⑓ࢫࢡ࣮ࣜࢽࣥࢢࢸࢫࢺࠕ⬻ࡢ೺ᗣデ᩿ࠖࡢ᭷⏝ᛶ. ➨ 51 ᅇ᪥ᮏ⚄⤒Ꮫ఍⥲఍, 2010.5.20-22 ᮾி

4. ྜྷᒣᐜṇ: ࢔ࣝࢶࣁ࢖࣐࣮⑓ࡢ᭱᪂἞⒪࣭἞⒪⸆ࡢືྥ. ➨ 14 ᅇ༓ⴥㄆ▱⑕◊✲఍ 2010.6.19 ༓ⴥ5. ຍ⸨㯞⨾ࠊ⏨⃝⪽Ꮚࠊ㕥ᮌ㐶ࠊ⡿ᕝᩔᏊࠊ୰ᮧ࿴௦ࠊ᪂஭බேࠊྜྷᒣᐜṇࠊఀ⸨႐⨾Ꮚ ➽ⴎ⦰⦰ᛶഃ⣴◳໬⑕㸦ALS㸧ᝈ⪅࣭ᐙ᪘࡬ࡢᚰ⌮ᨭ᥼࡟ࡘ࠸࡚̿┳ㆤᖌ࡜ᚰ⌮⒪ἲኈࡢ༠ാ̿ ➨ 2 ᅇ㛵ᮾಙ㉺ࣈࣟࢵࢡ⚄⤒࣭➽⑌ᝈࢿࢵࢺ࣮࣡ࢡ◊✲఍, 2010.6.25 ༓ⴥ

6.ྜྷᒣᐜṇ: ࢫࢱࢹ࢕࣮ࢢ࣮ࣝࣉ 3㸸ḟୡ௦ࡢᑐㄆ▱⑕ᡓ␎. ➨ 20 ᅇ᪥ᮏ⮫ᗋ⢭⚄⸆⌮Ꮫ఍ࠊ➨ 40 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ 2010.9.15 ௝ྎ
7. ྜྷᒣᐜṇ: ⱝᖺᛶㄆ▱⑕. ➨ 58 ᅇ᪥ᮏ⫋ᴗ࣭⅏ᐖ་Ꮫ఍Ꮫ⾡኱఍ 2010.11.5 ᾆᏳ
8. ຍ⸨㯞⨾ࠊ⏨⃝⪽Ꮚࠊ㕥ᮌ㐶ࠊ⡿ᕝᩔᏊࠊ୰ᮧ࿴௦ࠊ᪂஭බேࠊྜྷᒣᐜṇࠊఀ⸨႐⨾Ꮚ ➽ⴎ⦰ᛶഃ⣴◳໬⑕㸦ALS㸧ᝈ⪅࣭ᐙ᪘࡬ࡢᚰ⌮ᨭ᥼࡟ࡘ࠸࡚ 㸫┳ㆤᖌ࡜ᚰ⌮⒪ἲኈࡢ༠ാ㸫 ➨ 64 ᅇᅜ❧⑓㝔⥲ྜ་Ꮫ఍㸪 2010.11.26-27 ⚟ᒸ
9. ྜྷᒣᐜṇࠊఀ⸨႐⨾Ꮚࠊ᪂஭බேࢻࢿ࣌ࢪࣝ㸦࢔ࣜࢭࣉࢺ㸧ࡢᢠ⅖⑕స⏝ࡀ⚄⤒ኚᛶࢆᢚไࡍࡿ ➨ 1214 ᅇ༓ⴥ་Ꮫ఍౛఍㸪 2010.12.11 ༓ⴥ㹁㸬ㅮ₇఍࣭◊✲఍
1. ྜྷᒣᐜṇ 㛗⏕ㄆ▱⑕◊✲఍࡛ࡢㅮᖌ࣭2010/5/18࣭༓ⴥ
2. ྜྷᒣᐜṇ ⚄⤒ෆ⛉◊ಟࢭ࣑ࢼ࣮㸰㸮㸯㸮๓ᮇ࡛ࡢㅮᖌ࣭2010/7/1࣭༓ⴥ
3. ྜྷᒣᐜṇ 㬞ᕝㄆ▱⑕࢝ࣥࣇ࢓ࣞࣥࢫ࡛ࡢㅮᖌ࣭2010/7/2࣭༓ⴥ
4. ྜྷᒣᐜṇ ➨㸯ᅇᮾ㔠ㄆ▱⑕ࢡࣜࢽ࢝ࣝ࢝ࣥࣇ࢓ࣞࣥࢫࢭ࣑ࢼ࣮࡛ࡢㅮᖌ࣭2010/7/21࣭
༓ⴥ
5. ྜྷᒣᐜṇ ➨㸯ᅇᡂᮾㄆ▱⑕ࢡࣜࢽ࢝ࣝ࢝ࣥࣇ࢓ࣞࣥࢫࢭ࣑ࢼ࣮࡛ࡢㅮᖌ࣭2010/7/28࣭
༓ⴥ
6. ྜྷᒣᐜṇ ➨㸯ᅇᮾ㔠ㄆ▱⑕ࢡࣜࢽ࢝ࣝ࢝ࣥࣇ࢓ࣞࣥࢫࢭ࣑ࢼ࣮㸦㸰ᅇ┠㸧࡛ࡢㅮᖌ࣭
2010/8/18࣭༓ⴥ
7. ྜྷᒣᐜṇ ➨㸯ᅇᡂᮾㄆ▱⑕ࢡࣜࢽ࢝ࣝ࢝ࣥࣇ࢓ࣞࣥࢫࢭ࣑ࢼ࣮㸦㸰ᅇ┠㸧࡛ࡢㅮᖌ࣭
2010/8/25࣭༓ⴥ
8. ྜྷᒣᐜṇ ࠕ࠶ࡁࡽࡵ࡞࠸ ᭱᪂་⒪࡜ᨭ࠼ࡿ♫఍ࠖㄆ▱⑕ࣇ࢛࣮࣒࡛ࣛࡢㅮᖌ࣭

2010/9/4࣭༓ⴥ
9. ྜྷᒣᐜṇ ᖹᡂ㸰㸰ᖺᗘᅾᏯࢣ࢔◊ಟ఍࡛ࡢㅮᖌ࣭2010/9/12࣭༓ⴥ
10.ྜྷᒣᐜṇ ➨㸯ᅇᮾ㔠ㄆ▱⑕ࢡࣜࢽ࢝ࣝ࢝ࣥࣇ࢓ࣞࣥࢫࢭ࣑ࢼ࣮㸦㸱ᅇ┠㸧࡛ࡢㅮᖌ࣭
2010/9/22࣭༓ⴥ
11.ྜྷᒣᐜṇ ➨㸯ᅇ Chiba Dementia Conference ࡛ࡢㅮᖌ࣭2010/9/29࣭༓ⴥ
12.ྜྷᒣᐜṇ ༓ⴥᕷ་ᖌ఍ㄆ▱⑕ᕷẸබ㛤ㅮᗙ࡛ࡢㅮᖌ࣭2010/10/16࣭༓ⴥ
13.ྜྷᒣᐜṇ ➨㸯ᅇᡂᮾㄆ▱⑕ࢡࣜࢽ࢝ࣝ࢝ࣥࣇ࢓ࣞࣥࢫࢭ࣑ࢼ࣮㸦㸱ᅇ┠㸧࡛ࡢㅮᖌ࣭
2010/10/20࣭༓ⴥ
14.ྜྷᒣᐜṇ ࠕࡳࢇ࡞࡛ᨭ࠼ࡿㄆ▱⑕ࠊࡑࡢࡓࡵ࡟ᚲせ࡞▱㆑ࠖᕷᕝᕷ௓ㆤᨭ᥼ᑓ㛛ဨ༠㆟఍ཬࡧᕷᕝᕷ་ᖌ఍ྜྠ◊ಟ఍࡛ࡢㅮᖌ࣭2011/1/15࣭༓ⴥ
15.ྜྷᒣᐜṇ ➨㸰ᅇⰼぢᕝ༊ㄆ▱⑕἞⒪ࢆ⪃࠼ࡿ఍࡛ࡢㅮᖌ࣭2011/1/27࣭༓ⴥ㹂㸬◊✲ຓᡂ㔠⋓ᚓ≧ἣ⛉Ꮫ◊✲㈝(C) ࠕ࣓ࢱ࣎ࣜࢵࢡࢩࣥࢻ࣮࣒ࣟࠖ࡜ㄆ▱⑕ࡢ㛵㐃ࡢゎ᫂㸸ㄆ▱⑕ࣔࢹ࣐ࣝ࢘ࢫࢆ⏝࠸ࡓ◊✲ ྜྷᒣᐜṇ἞㦂ᐇ᪋≧ἣ

1. SUN Y7017㸦࣓࣐ࣥࢳࣥሷ㓟ሷ㸧ࡢ㧗ᗘ࢔ࣝࢶࣁ࢖࣐࣮ᆺ⑵࿈࡟ᑐࡍࡿ㛗ᮇヨ㦂
2. E0302 ࡢ➽ⴎ⦰ᛶഃ⣴◳໬⑕࡟ᑐࡍࡿ⮫ᗋ➨ II㸭III ┦ヨ㦂
3. E0302 ࡢ➽ⴎ⦰ᛶഃ⣴◳໬⑕࡟ᑐࡍࡿ㛗ᮇヨ㦂
4. E2020 ࡢࣞࣅ࣮ᑠయᆺㄆ▱⑕㸦DLB㸧ࢆᑐ㇟࡜ࡋࡓ⥅⥆㛗ᮇᢞ୚ヨ㦂
5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001,ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are
Apolipoprotein E Ȝ4 Carriers㹙࢔࣏࣏ࣜࢱࣥࣃࢡ EȜ4 ࢆ᭷ࡍࡿ㍍ᗘ㹼୰➼ᗘࡢ࢔ࣝࢶࣁ࢖࣐࣮ᆺㄆ▱⑕ᝈ⪅ࢆᑐ㇟࡜ࡋࡓ AAB-001 ࡢ᭷ຠᛶ࠾ࡼࡧᏳ඲ᛶࢆ᳨ウࡍࡿ➨ 3 ┦㸪ከ᪋タඹྠ㸪↓సⅭ໬㸪஧㔜┣᳨㸪ࣉࣛࢭ࣎ᑐ↷㸪୪⾜⩌㛫ヨ㦂㹛
6. Ropinirole PR/XR 㘄ࡢ L-dopa 〇๣ే⏝ࡢࣃ࣮࢟ࣥࢯࣥ⑓ᝈ⪅࡟ᑐࡍࡿ⮫ᗋホ౯
7. SPM962 ࡢ L-dopa ే⏝ୗࣃ࣮࢟ࣥࢯࣥ⑓ᝈ⪅ࢆᑐ㇟࡜ࡋࡓࣉࣛࢭ࣎ཬࡧࣟࣆࢽ࣮ࣟࣝࢆᑐ㇟࡜ࡋࡓ஧㔜┣᳨㸱⩌㛫ẚ㍑ヨ㦂
8. SPM962 ࡢ L-dopa ే⏝ୗࣃ࣮࢟ࣥࢯࣥ⑓ᝈ⪅ࢆᑐ㇟࡜ࡋࡓ➨ III ┦ヨ㦂㸦243-08-001㸧ࡢ⥅⥆㛗ᮇᢞ୚ヨ㦂
9. ㍍ᗘ࠿ࡽ୰➼ᗘࡢ࢔ࣝࢶࣁ࢖࣐࣮ᆺㄆ▱⑕እ᮶ᝈ⪅ࢆᑐ㇟࡜ࡋࡓ 3 ⏝㔞ࡢ
SAM-531 ࢆ 52 㐌㛫ᢞ୚ࡋࡓ᫬ࡢ᭷ຠᛶཬࡧᏳ඲ᛶࢆホ౯ࡍࡿ,2 ᮇ,ከ᪋タඹྠ,↓సⅭ໬,஧㔜┣᳨,ࢻࢿ࣌ࢪࣝሷ㓟ሷཧ↷㸪ࣉࣛࢭ࣎ᑐ↷ẚ㍑ヨ㦂
10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001,ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are
Apolipoprotein E Ȝ4 Non-carriers㹙࢔࣏࣏ࣜࢱࣥࣃࢡ EȜ4 ࢆ᭷ࡉ࡞࠸㍍ᗘ
㹼୰➼ᗘࡢ࢔ࣝࢶࣁ࢖࣐࣮ᆺㄆ▱⑕ᝈ⪅ࢆᑐ㇟࡜ࡋࡓ AAB-001 ࡢ᭷ຠᛶ࠾ࡼࡧᏳ඲ᛶࢆ᳨ウࡍࡿ➨ 3 ┦㸪ከ᪋タඹྠ㸪↓సⅭ໬㸪஧㔜┣᳨㸪ࣉࣛࢭ࣎ᑐ↷㸪୪⾜⩌㛫ヨ㦂㹛
11. KW-6500 ➨Ϫ┦⮫ᗋヨ㦂 (ࣃ࣮࢟ࣥࢯࣥ⑓ᝈ⪅ࢆᑐ㇟࡜ࡋࡓ㛗ᮇࡢᅾᏯ⮬ᕫὀᑕ࡟࠾ࡅࡿᏳ඲ᛶヨ㦂)
12. 3133K1-3001-WW ヨ㦂࡟ཧຍࡋࡓ࢔࣏࣏ࣜࢱࣥࣃࢡ EȜ4 ࢆ᭷ࡍࡿ࢔ࣝࢶࣁ࢖࣐࣮ᆺㄆ▱⑕ᝈ⪅ࢆᑐ㇟࡜ࡋࡓ AAB-001 ࡢ㛗ᮇⓗᏳ඲ᛶཬࡧᚸᐜᛶࢆ᳨ウࡍࡿ➨ 3 ┦ࠊከ᪋タඹྠࠊ㛗ᮇ⥅⥆ᢞ୚ヨ㦂
13. 3133K1-3001-WW ヨ㦂࡟ཧຍࡋࡓ࢔࣏࣏ࣜࢱࣥࣃࢡ EȜ4 ࢆ᭷ࡉ࡞࠸࢔ࣝࢶࣁ࢖࣐࣮ᆺㄆ▱⑕ᝈ⪅ࢆᑐ㇟࡜ࡋࡓ AAB-001 ࡢ㛗ᮇⓗᏳ඲ᛶཬࡧᚸᐜᛶࢆ᳨ウࡍࡿ➨ 3 ┦ࠊከ᪋タඹྠࠊ㛗ᮇ⥅⥆ᢞ୚ヨ㦂
14. ୰➼⑕㹼㔜⑕ࣃ࣮࢟ࣥࢯࣥ⑓᪥ᮏேᝈ⪅ࢆᑐ㇟࡜ࡋࡓࣉࣞࣛࢹࢼࣥࢺࢆ㸯㸰㐌㛫ᢞ୚ࡋࡓ㝿ࡢ᭷ຠᛶཬࡧᏳ඲ᛶࢆホ౯ࡍࡿ➨ϩ┦ࠊከ᪋タඹྠࠊ↓సⅭ໬ࠊ஧㔜┣᳨ࠊࣉࣛࢭ࣎ᑐ↷⏝㔞タᐃヨ㦂
15. E2020 ࡢࣞࣅ࣮ᑠయᆺㄆ▱⑕㸦DLB㸧ࢆᑐ㇟࡜ࡋࡓ஧㔜┣᳨୪⾜⩌㛫ẚ㍑ཬࡧ⥅⥆㛗ᮇᢞ୚ヨ㦂㹄㸬ࡑࡢ௚
1. ㄢ㢟ྡ㸸㍍ᗘㄆ▱ᶵ⬟㞀ᐖ (MCI)࠿ࡽึᮇ࢔ࣝࢶࣁ࢖࣐࣮⑓࡟⛣⾜ࡍࡿ㝿ࡢᐈほⓗ࡞ᣦᶆ࡜ᇶ‽್ࢆ᥈ࡿࡓࡵࡢඹྠヨ㦂 (J-ADNI㸸Japanese Alzheimer's Disease
Neuroimaging Initiative) ୺௵◊✲⪅ྡ㸸ᮾி኱Ꮫ ஭ཎᗣኵ ඹྠ◊✲⪅ྡ㸸ྜྷᒣᐜṇ
2. ᪂⪺グ஦ ㄞ኎᪂⪺ 9 ᭶ 28 ᪥ ᮅห